Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Triaminic Thin Strips are a line of over-the-counter (OTC) pediatric medications developed by Novartis, specifically designed as oral disintegrating films (thin strips) that dissolve on the tongue. Launched in 2004, these products are intended for children aged 4 and older to relieve symptoms of the common cold, flu, and respiratory allergies. The product line includes several formulations: the Day Time Cold & Cough version combines dextromethorphan (a cough suppressant) and phenylephrine (a nasal decongestant); the Cough & Runny Nose version contains diphenhydramine (an antihistamine); and the Night Time Cold & Cough version combines diphenhydramine and phenylephrine. These small molecule drugs work by targeting specific receptors to suppress cough, reduce nasal congestion, and alleviate allergic symptoms like runny nose and sneezing.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Triaminic Thin Strips.